Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor. Tesofensine inhibits presynaptic reuptake of noradrenaline, dopamine and serotonin, raising synaptic concentrations of all three. Appetite suppression in clinical studies is attributed mainly to noradrenergic and dopaminergic signalling in hypothalamic circuits regulating food intake.
For research use only.
Key Facts
- CAS
- 195875-84-4
- Molecular Weight (MW)
- 328.3 g/mol
- Half-life
- —
- FDA status
- Investigational New Drug (IND)
- Administration Route
- oral
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Oct 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 21
- Listed offers
- 27
- Price per mg (peptide vials)
- $180.00/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials1 vendor · $180.00/mg
- Capsules15 vendors · median $3.83/mg
- Tablets6 vendors · median $7.17/mg
Research summary
Small-molecule triple monoamine reuptake inhibitor originally developed for neurodegenerative disease and later investigated for obesity. Not FDA-approved. It is widely sold as a research chemical despite having no approved indication in the United States.
Peptide Library's Tesofensine profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- oral
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Tesofensine is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C17H23Cl2NO |
|---|---|
| Molecular weight | 328.3 g/mol |
| CAS number | 195875-84-4 |
| PubChem CID | 11370864 |
| FDA UNII | BLH9UKX9V1 |
| ChEMBL | CHEMBL3989690 |
| DrugBank | DB06156 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Tesofensine inhibits presynaptic reuptake of noradrenaline, dopamine and serotonin, raising synaptic concentrations of all three. Appetite suppression in clinical studies is attributed mainly to noradrenergic and dopaminergic signalling in hypothalamic circuits regulating food intake. Its monoaminergic activity also underlies the cardiovascular effects — increases in heart rate and blood pressure — reported in trials.
Studies
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease
- The effect of tesofensine on appetite sensations
- Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine
- Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
- Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity
Regulatory & research status
Tesofensine has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Research status | Investigational; clinical development reported |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
Benefits
—
Tesofensine side effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Tesofensine: frequently asked questions
What is Tesofensine?
Small-molecule triple monoamine reuptake inhibitor originally developed for neurodegenerative disease and later investigated for obesity. Not FDA-approved. It is widely sold as a research chemical despite having no approved indication in the United States.
How does Tesofensine work?
Tesofensine inhibits presynaptic reuptake of noradrenaline, dopamine and serotonin, raising synaptic concentrations of all three. Appetite suppression in clinical studies is attributed mainly to noradrenergic and dopaminergic signalling in hypothalamic circuits regulating food intake.
Is Tesofensine FDA approved?
No. Tesofensine is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What peptides are similar to Tesofensine?
Compounds most often compared with Tesofensine include 5-Amino-1MQ, SLU-PP-332, BAM15 and AICAR. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease — Obesity (Silver Spring), 2008External reference
- The effect of tesofensine on appetite sensations — Obesity (Silver Spring), 2012External reference
- Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine — AAPS J, 2010External reference
- Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity — Eur J Endocrinol, 2022External reference
- Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity — Curr Opin Investig Drugs, 2009External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Tesofensine profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Tesofensine research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →